Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - Multiparametric MR imaging for detection and biopsy planning

Radiology

Volumn 259, Issue 1, 2011, Pages 162-172

  Franiel, Tobias ^a   Stephan, Carsten ^a   Erbersdobler, Andreas ^b   Dietz, Ekkehart ^a   Maxeiner, Andreas ^a   Hell, Nina ^a   Huppertz, Alexander ^a   Miller, Kurt ^a   Strecker, Ralph ^c   Hamm, Bernd ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Healthcare Sector   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CITRIC ACID; CREATININE; GADOLINIUM PENTETATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECTUM; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURGERY, COMPUTER-ASSISTED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79953002507     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10101251     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
2. American Urological Association. Guideline for management of clinically localized prostate cancer: 2007 update. http://www.auanet.org /content/guidelines-and-quality-care/clinical-guidelines/ main-reports/ proscan07/content.pdf. Published 2007. Accessed 2010.
3. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151(6):1571-1574. (Pubitemid 24151304)
4. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167(6):2435-2439. (Pubitemid 34533140)
5. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005;234(2):576-581. (Pubitemid 40139933)
6. Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006;50(4):738-748; discussion 748-749.
7. Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K, Engehausen D. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 2006;16(6):1237-1243. (Pubitemid 43834709)
8. Beyersdorff D, Taupitz M, Winkelmann B, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002;224(3):701-706. (Pubitemid 34919801)
9. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1 H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008;246(2):480-488.
10. Puech P, Potiron E, Lemaitre L, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009;74(5):1094-1099.
11. 3) spatial resolution. Radiology 1996;198(3):795-805.
12. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28(3):720-726.
13. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3):223-232.
14. Brix G, Kiessling F, Lucht R, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004;52(2):420-429. (Pubitemid 39025290)
15. Hambrock T, Fütterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 2008;43(10):686-694.
16. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53(1):68-80. (Pubitemid 350166735)
17. Wang HZ, Riederer SJ, Lee JN. Optimizing the precision in T1 relaxation estimation using limited flip angles. Magn Reson Med 1987;5(5):399-416. (Pubitemid 17167630)
18. Walker-Samuel S, Leach MO, Collins DJ. Reference tissue quantification of DCE-MRI data without a contrast agent calibration. Phys Med Biol 2007;52(3):589-601. (Pubitemid 46646433)
19. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med 1991;17(2):357-367.
20. Parker GJ, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006;56(5):993-1000. (Pubitemid 44691341)
21. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006;239(3):784-792. (Pubitemid 43830614)
22. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189(2):323-328. (Pubitemid 47195916)
23. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 suppl):933-938.
24. de Oliveira A, Rauschenberg J, Beyersdorff D, Semmler W, Bock M. Automatic passive tracking of an endorectal prostate biopsy device using phase-only cross-correlation. Magn Reson Med 2008;59(5):1043-1050.
25. Fütterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42(2):116-122. (Pubitemid 46104892)
26. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004;233(3):709-715.
27. van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20(2):279-287. (Pubitemid 38970937)
28. Scheenen T, Weiland E, Fütterer J, et al. Preliminary results of IMAPS: an international multi-centre assessment of prostate MR spectroscopy [abstr]. In: Proceedings of the Thirteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2005.
29. Tamada T, Sone T, Toshimitsu S, et al. Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging 2008;27(3):552-556. (Pubitemid 351354740)
30. Schwenke C, Busse R. Analysis of differences in proportions from clustered data with multiple measurements in diagnostic studies. Methods Inf Med 2007;46(5):548-552. (Pubitemid 47598972)
31. Riches SF, Payne GS, Morgan VA, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009;193(6):1583-1591.
32. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12(12):897-906. (Pubitemid 19011040)
33. Presti JC Jr. Repeat prostate biopsy: when, where, and how. Urol Oncol 2009;27(3):312-314.
34. e, and corresponding histologic features. Radiology 2010;255(2):485-494.
35. Walker-Samuel S, Orton M, McPhail LD, Robinson SP. Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors. Magn Reson Med 2009;62(2):420-429.
36. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001;14(4):457-463. (Pubitemid 32906564)
37. Port RE, Knopp MV, Brix G. Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med 2001;45(6):1030-1038.
38. Franiel T, Lüdemann L, Rudolph B, et al. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 2009;252(1):101-108.
39. Shukla-Dave A, Hricak H, Moskowitz C, et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007;245(2):499-506. (Pubitemid 47612532)
40. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006;24(5):563-568. (Pubitemid 43776563)